Treatment with an antibody against VAP-1 also prevents hepatic fibrosis in murine models of liver injury, with loss of VAP-1 enzyme activity or antibody blockade leading to a reduction in the recruitment of immune cells into inflamed tissue.13 The gene discussed is AOC3; the disease is Hepatic fibrosis.